Europe — EMA

Oxlumo (Lumasiran)

Lumasiran, the active ingredient in Oxlumo, is an RNA‑RNA therapeutic presented as a solution for subcutaneous injection use. It treats primary hyperoxaluria type 1 in patients of all ages.

Lumasiran

Request sourcing

Pack/s

What is Lumasiran?

Lumasiran, the active ingredient in Oxlumo, is an RNA‑RNA therapeutic presented as a solution for subcutaneous injection use. It treats primary hyperoxaluria type 1 in patients of all ages.

GNH USA supplies Oxlumo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Lumasiran used for?

Oxlumo targets the hepatic glycolytic pathway of primary primary ... .... . - Primary Hyper‑ ... : … … . - ... .... ... ... .... ... … ... ... ... ... ... ... ... """" " " " " " " " ".

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →